Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
Boehringer Ingelheim has filed for a label expansion of Hernexeos (zongertinib) in Japan, seeking approval for use as a first-line treatment in patients with HER2 (ERBB2)-mutated unresectable, advanced or recurrent non-small cell lung cancer (NSCLC). Hernexeos hit the Japanese market…
To read the full story
Related Article
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…